RNAi therapeutics for Friedreich ataxia

Friedreich 共济失调的 RNAi 疗法

• 批准号: 7530372
• 负责人: ROBERT B WILSON
• 金额: $ 19.69万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7530372
• 关键词: Back; Biological; Biological Assay; Cells; Chemicals; Communicable Diseases; Condition; Degenerative Disorder; Development; Disease; Exhibits; Fibroblasts; Friedreich Ataxia; Gene Expression; Genes; Hereditary Disease; Laboratories; Lead; Libraries; Life; Methods; Mitochondria; Molecular Profiling; Oxidative Stress; Phenotype; Polymerase Chain Reaction; Preclinical Drug Evaluation; Proteins; Public Health; RNA Interference; Randomized; Retroviral Vector; Retroviridae; Role; Screening procedure; Signs and Symptoms; Testing; Therapeutic; Therapeutic Index; Time; Yeast Model System; base; design; frataxin; improved; interest; mitochondrial dysfunction; novel; novel therapeutics; small hairpin RNA; therapeutic target

DESCRIPTION (provided by applicant): Friedreich ataxia (FRDA) is an autosomal recessive neuro- and cardio-degenerative disorder for which there are currently no established effective treatments. The identification of the disease gene in 1996 and the subsequent elucidation of the function of the encoded protein, frataxin, have opened the door to possible therapeutic approaches, including conventional high-throughput drug screening. This proposal describes a novel, complementary approach to the development of therapeutics for FRDA. We devised a method to construct a library that encodes random, short-hairpin-loop RNAs (shRNAs). This library can be used to identify shRNA sequences of therapeutic, therapeutic-targeting, and/or biological interest. The identification is based on functional selection, with effective sequences retrieved by PCR from cells that survive a particular condition or exhibit a predetermined phenotype. The design allows for hit-optimization of effective sequences, with re-selection for sequences with improved effects. Using primary FRDA fibroblasts, we developed screening and selection assays based on the critical role of mitochondrial dysfunction in the signs and symptoms of FRDA and on the sensitivity of FRDA cells to oxidative stress. With our live/dead selection assays, we can use our random shRNA-encoding library to identify shRNA sequences of benefit to FRDA cells. With our screening assays of mitochondrial function, we can confirm and prioritize these sequences. The primary objective of this proposal is to identify potential shRNA therapeutics. A secondary objective is to begin to understand the mechanisms of action of the shRNAs we identify. The Specific Aims are: 1. To identify shRNA sequences that allow survival under conditions lethal to primary FRDA fibroblasts but non-lethal to normal control cells. 2. To optimize the shRNA sequences identified in Aim 1. 3. To confirm and prioritize optimized shRNAs and begin to understand mechanisms of action. This proposal describes an approach to develop novel therapeutics for Friedreich ataxia using a random shRNA library. This approach has potential implications for the development of therapeutics for other genetic diseases, as well as for infectious diseases, and is therefore highly relevant to public health.

描述（由申请人提供）： 弗里德赖希共济失调（FRDA）是一种常染色体隐性遗传的神经和心脏退行性疾病，目前尚无有效的治疗方法。1996年对疾病基因的鉴定以及随后对编码蛋白Frataxin功能的阐明，为可能的治疗方法打开了大门，包括常规的高通量药物筛选。该提案描述了一种新的，互补的方法来开发FRDA的治疗方法。我们设计了一种方法来构建编码随机短发夹环RNA（shRNA）的文库。该文库可用于鉴定治疗性、治疗靶向和/或生物学目的的shRNA序列。鉴定是基于功能选择，通过PCR从在特定条件下存活或表现出预定表型的细胞中检索有效序列。该设计允许有效序列的命中优化，并重新选择具有改善效果的序列。使用原代FRDA成纤维细胞，我们开发了基于线粒体功能障碍在FRDA体征和症状中的关键作用以及FRDA细胞对氧化应激的敏感性的筛选和选择测定。通过我们的活/死选择试验，我们可以使用我们的随机shRNA编码文库来鉴定对FRDA细胞有益的shRNA序列。通过我们对线粒体功能的筛选测定，我们可以确认这些序列并对其进行优先排序。该提案的主要目的是确定潜在的shRNA治疗方法。第二个目标是开始了解我们鉴定的shRNA的作用机制。具体目标是：1。鉴定允许在对原代FRDA成纤维细胞致死但对正常对照细胞非致死的条件下存活的shRNA序列。2.优化目标1中确定的shRNA序列。3.确认并优先考虑优化的shRNA，并开始了解其作用机制。该提案描述了一种使用随机shRNA文库开发Friedreich共济失调新疗法的方法。这种方法对其他遗传疾病以及传染病的治疗方法的发展具有潜在的影响，因此与公共卫生高度相关。